Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation

Transplantation

Volumn 83, Issue 2, 2007, Pages 231-233

  Takaki, Akinobu ^a,b   Yagi, Takahito ^a   Iwasaki, Yoshiaki ^a   Sadamori, Hiroshi ^a   Matsukawa, Hiroyoshi ^a   Matsuda, Hiroaki ^a   Shinoura, Susumu ^a   Umeda, Yuuzou ^a   Miyake, Yasuhiro ^a   Terada, Ryou ^a   Kobashi, Haruhiko ^a   Sakaguchi, Kohsaku ^a   Tanaka, Noriaki ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Hepatitis B; Hepatitis B immunoglobulin; Lamivudine; Liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; AZATHIOPRINE; CYCLOSPORIN A; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG DOSE TITRATION; FOLLOW UP; GRAFT REJECTION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL;

DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; LAMIVUDINE; LIVER TRANSPLANTATION; RECURRENCE; TIME FACTORS;

EID: 33846587003     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000246310.75638.86     Document Type: Article

References (21)

1. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004; 78: 955.
2. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
3. Lo CM, Cheung ST, Lai CL, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233: 276.
4. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212.
5. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581.
6. Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30: 715.
7. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585.
8. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429.
9. Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491.
10. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10 (suppl 2): S74.
11. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811.
12. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given 'on demand' in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203.
13. Ferretti G, Merli M, Ginanni Corradini S, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 2004; 36: 535.
14. Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 921.
15. Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984; 1: 921.
16. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50: 1.
17. Schilling R, Ijaz S, Davidoff M, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003; 77: 8882.
18. Muller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13: 90.
19. Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841.
20. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213.
21. Piao CY, Fujioka S, Iwasaki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort. Acta Med Okayama 2005; 59: 217.